Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
SAN CARLOS, Calif., Oct. 25, 2017 -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its third quarter 2017 financial and operating results after the close of the U.S. financial markets on Tuesday, October 31, 2017. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET.
In order to participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-247-0257 (international) and reference the access code 1423064. The live webcast can be accessed under “News & Events” in the “Investors” section of the Company’s website at http://www.iovance.com/ or you may use the link: https://edge.media-server.com/m6/p/q7762k6j.
A replay of the call will be available from October 31, 2017 at 7:00 p.m. ET to November 30, 2017 at 8:30 p.m. ET. To access the replay, please dial 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and reference the access code 1423064. The archived webcast will be available for thirty days in the Investors section of Iovance Biotherapeutics’ website at http://www.iovance.com/.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The Company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck and recurrent and metastatic or persistent cervical cancer. For more information, please visit http://www.iovance.com.
Investor Contact:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
[email protected]
Media Contact:
Evan Smith/Kotaro Yoshida
FTI Consulting
212-850-5622/212-850-5690
[email protected]
[email protected]
